Cargando…

Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses

BACKGROUND: As a risk-mitigation strategy to minimize paralytic polio following withdrawal of Sabin type 2 from the oral poliovirus vaccine in April 2016, a single full dose or 2 fractional doses of inactivated poliovirus vaccine (IPV) are recommended. However, limited knowledge exists on long-term...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhaumik, Siddhartha Kumar, Kulkarni, Raveendra R, Weldon, William C, Silveira, Eduardo L V, Ahmed, Hasan, Gunisetty, Sivaram, Chandele, Anmol, Antia, Rustom, Verma, Harish, Sutter, Roland, Pallansch, Mark A, Oberste, M Steven, Villinger, Francois, Orenstein, Walter, Murali-Krishna, Kaja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206122/ https://www.ncbi.nlm.nih.gov/pubmed/30376091 http://dx.doi.org/10.1093/cid/ciy634

Ejemplares similares

Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States
por: Marin, Mona, et al.
Publicado: (2017)

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar
por: Razafindratsimandresy, Richter, et al.
Publicado: (2018)

Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria
por: Iliyasu, Zubairu, et al.
Publicado: (2016)

Achieving high seroprevalence against polioviruses in Sri Lanka-Results from a serological survey, 2014
por: Gamage, Deepa, et al.
Publicado: (2015)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Seroprevalence of Poliovirus Antibodies in the United States Population, 2009–2010
por: Wallace, Gregory S., et al.
Publicado: (2016)

Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria
por: Verma, Harish, et al.
Publicado: (2018)

Survey of poliovirus antibodies in Borno and Yobe States, North-Eastern Nigeria
por: Gofama, Mustapha Modu, et al.
Publicado: (2017)

Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan
por: Saleem, Ali Faisal, et al.
Publicado: (2017)

Cloning, expression and purification of Chikungunya virus E2 recombinant protein in E.coli
por: Kr Verma, Anil, et al.
Publicado: (2014)

Dengue Virus Non-Structural Protein 5 as a Versatile, Multi-Functional Effector in Host–Pathogen Interactions
por: Bhatnagar, Priya, et al.
Publicado: (2021)

Immunogenicity of poliovirus vaccines in chronically malnourished infants: A randomized controlled trial in Pakistan
por: Saleem, Ali Faisal, et al.
Publicado: (2015)

Optimization of Flow-Cytometry Based Assay for Measuring Neutralizing Antibody Responses against Each of the Four Dengue Virus Serotypes
por: Sharma, Pragati, et al.
Publicado: (2021)

Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency virus infected children in Kenya
por: Khetsuriani, Nino, et al.
Publicado: (2009)

Cold chain and virus‐free chloroplast‐made booster vaccine to confer immunity against different poliovirus serotypes
por: Chan, Hui‐Ting, et al.
Publicado: (2016)

Contrasting behavior between the three human monocyte subsets in dengue pathophysiology
por: Maheshwari, Deepti, et al.
Publicado: (2022)

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal()
por: Harutyunyan, Vachagan, et al.
Publicado: (2023)

Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan
por: Saleem, Ali Faisal, et al.
Publicado: (2018)

Characterization of Human CD8 T Cell Responses in Dengue Virus-Infected Patients from India
por: Chandele, Anmol, et al.
Publicado: (2016)

Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia
por: Bashorun, Adedapo O, et al.
Publicado: (2021)

Role of enterovirus 71 in acute flaccid paralysis after the eradication of poliovirus in Brazil.
por: da Silva, E E, et al.
Publicado: (1996)

A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2020)

Interim CDC Guidance for Polio Vaccination for Travel to and from Countries Affected by Wild Poliovirus
por: Wallace, Gregory S., et al.
Publicado: (2014)

Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–June 2019
por: Jorba, Jaume, et al.
Publicado: (2019)

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies
por: Resik, Sonia, et al.
Publicado: (2015)

Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique
por: de Deus, Nilsa, et al.
Publicado: (2020)

The role of supplementary environmental surveillance to complement acute flaccid paralysis surveillance for wild poliovirus in Pakistan – 2011–2013
por: Cowger, Tori L., et al.
Publicado: (2017)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

Interleukin 15 Is Required for Proliferative Renewal of Virus-specific Memory CD8 T Cells
por: Becker, Todd C., et al.
Publicado: (2002)

Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters
por: Kalkowska, D. A., et al.
Publicado: (2019)

An economic analysis of poliovirus risk management policy options for 2013–2052
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice
por: Ramasamy, Viswanathan, et al.
Publicado: (2018)

Outbreak response strategies with type 2-containing oral poliovirus vaccines ()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials
por: Sáez-Llorens, Xavier, et al.
Publicado: (2021)

Estimating the Extent of Vaccine-Derived Poliovirus Infection
por: Wringe, Alison, et al.
Publicado: (2008)

Progress Toward Poliovirus Containment Implementation — Worldwide, 2018–2019
por: Moffett, Daphne B., et al.
Publicado: (2019)

Emergence of Vaccine-derived Polioviruses, Democratic Republic of Congo, 2004–2011
por: Gumede, Nicksy, et al.
Publicado: (2013)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
por: De Coster, Ilse, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2rch3ijfd1li0ui0vks94vajdn